(S)-4-[2-(dimethyl-phenyl-silanyl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester | 1205639-49-1

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: (S)-4-[2-(dimethyl-phenyl-silanyl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester
• 英文别名: (S)-4-[2-(dimethyl-phenyl-silanyl)ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester；tert-butyl (4S)-4-[2-[dimethyl(phenyl)silyl]ethyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
• CAS: 1205639-49-1
• 化学式: C₂₀H₃₃NO₃Si
• 分子量: 363.572
• InChiKey: YXXVBDBJBNOYOT-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.36
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-4-[2-(dimethyl-phenyl-silanyl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 在 盐酸 、 碳酸氢钠 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以77%的产率得到(S)-2-amino-4-(dimethyl-phenyl-silanyl)-butan-1-ol
  参考文献：
  名称：

  4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES

  摘要：

  该发明涉及公式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药学上可接受的酸盐。该发明还提供了制备这种化合物的药物组合物和方法。这些化合物可用于治疗与痕量胺相关受体的生物功能相关的疾病，这些疾病包括抑郁症、焦虑症、躁郁症、注意缺陷多动障碍、与压力有关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收异常、体温稳态异常、睡眠和昼夜节律异常、心血管疾病。

  公开号：

  US20100029589A1
• 作为产物：
  描述：

  二甲基苯基硅烷 、 (S)-2,2-二甲基-4-乙烯基噁唑啉-3-羧酸叔丁酯 在 二氧化铂 crude product 、 SiO2 、 ethyl acetate heptane 作用下， 反应 16.0h， 以to give (S)-4-[2-(dimethyl-phenyl-silanyl)ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester (1.14 g, 95%) as colourless oil, which的产率得到(S)-4-[2-(dimethyl-phenyl-silanyl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  4,5-dihydro-oxazol-2yl derivatives

  摘要：

  本发明涉及式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药物可接受的酸盐也包括在内。本发明还提供了制备这些化合物的药物组合物和方法。这些化合物可用于治疗与微量胺相关受体的生物功能有关的疾病，这些疾病包括抑郁症、焦虑症、双相障碍、注意力缺陷多动症、应激相关疾病、精神疾病、精神分裂症、神经疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、饮食失调、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和失灵、睡眠和昼夜节律障碍以及心血管疾病。

  公开号：

  US08357712B2

文献信息

• 4,5-dihydro-oxazol-2YL derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US08242153B2

  公开（公告）日：2012-08-14

  The invention relates to compounds of formula I wherein R1, R2, X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药学上可接受的酸盐。本发明还提供了制备这种化合物的制药组合物和方法。这些化合物对于治疗与微量胺相关受体的生物功能相关的疾病非常有用，这些疾病包括抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关疾病、精神疾病、精神分裂症、神经疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和睡眠和昼夜节律障碍以及心血管疾病。
• 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES
  申请人：Galley Guido

  公开号：US20100029589A1

  公开（公告）日：2010-02-04

  The invention relates to compounds of formula I wherein R 1 , R 2 , X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及公式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药学上可接受的酸盐。该发明还提供了制备这种化合物的药物组合物和方法。这些化合物可用于治疗与痕量胺相关受体的生物功能相关的疾病，这些疾病包括抑郁症、焦虑症、躁郁症、注意缺陷多动障碍、与压力有关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收异常、体温稳态异常、睡眠和昼夜节律异常、心血管疾病。
• 4,5-dihydro-oxazol-2yl derivatives
  申请人：Galley Guido

  公开号：US08357712B2

  公开（公告）日：2013-01-22

  The invention relates to compounds of formula I wherein R1, R2, X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药物可接受的酸盐也包括在内。本发明还提供了制备这些化合物的药物组合物和方法。这些化合物可用于治疗与微量胺相关受体的生物功能有关的疾病，这些疾病包括抑郁症、焦虑症、双相障碍、注意力缺陷多动症、应激相关疾病、精神疾病、精神分裂症、神经疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、饮食失调、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和失灵、睡眠和昼夜节律障碍以及心血管疾病。